ReviewFrontiers in endocrinology2025
Recent advances in biomarkers for diabetes mellitus and tuberculosis comorbidity: a comprehensive review.
Review in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Article
- Lipid metabolism in the resuscitation of dormant mycobacterium tuberculosis: molecular resilience, host hijacking, and clinical opportunities.Frontiers in cellular and infection microbiology · 2026Review
- The eight pillars of within-host tuberculosis modelling.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetes mellitus (DM) and tuberculosis (TB) are significant global health challenges that complicate diagnosis, treatment, and management due to their interrelated nature. DM increases TB risk and worsens outcomes, highlighting the need for early detection and effective management. This review summarizes recent advancements in biomarkers for DM-TB comorbidity, including microbial, metabolic, immunological, inflammatory, clinical, and genetic markers. We identified 30 relevant studies, through a literature search using keywords related to DM, TB, and biomarkers. Key findings include specific gut microbiota genera and lipid mediators that show promise for early diagnosis and treatment. Immunological biomarkers like altered CD8+ T cells and NK cells provide insights into disease severity and treatment monitoring. Inflammatory markers such as elevated CRP, ferritin, and IL-6 reflect heightened inflammation and could guide treatment strategies. Clinical biomarkers, including serum CA-125 (sensitivity 88.14%, specificity 95.83%) and AUC/MIC ratios of anti-TB drugs (e.g., moxifloxacin ≥67; sensitivity 97.3%, specificity 90.0%), demonstrate high diagnostic accuracy. Future research should focus on validating these biomarkers across diverse populations and integrating them into clinical practice to enhance DM-TB management and contribute to global disease control efforts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.